July 30. 2025 — Cardiosense, a medical AI company, recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the CardioTag device, a multimodal, wearable sensor that simultaneously captures high-fidelity electrocardiogram (ECG), photoplethysmogram (PPG), and seismocardiogram (SCG) signals, empowering clinicians and patients with a comprehensive noninvasive solution to assess cardiac function across care settings.

July 29, 2025 — The American Heart Association, a global force changing the future of health for all, is recognizing 158 hospitals across the nation with a new Commitment to Quality award that highlights high performance across three or more clinical areas in the Get With The Guidelines program. Hospitals earning this new award demonstrate a comprehensive approach to quality improvement for patient care.

July 23, 2025 — Conavi Medical Inc., a leader in hybrid intracoronary imaging technologies, is applauding the recent publication in The American Journal of Cardiology titled “Regional Disparities and Predictors of Intracoronary Imaging Use During Percutaneous Coronary Intervention in the United States.” This comprehensive analysis, based on more than 1.8 million patient records, underscores both the underutilization and growing clinical importance of intracoronary imaging (ICI) during percutaneous coronary interventions (PCI).

July 28, 2025 — Frost & Sullivan has named Siemens Healthineers the 2025 North America Company of the Year in the advanced visualization applications industry for its outstanding achievements in diagnostic innovation, seamless platform integration, and customer impact. This recognition underscores Siemens Healthineers' market leadership in transforming medical imaging with intelligent automation, scalable technology, and end-to-end workflow solutions.

July 28, 2025 — AngioDynamics, Inc. has announced enrollment of the first patient in the Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee (AMBITION BTK).

July 28, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its MAGiC Sweep catheter. MAGiC Sweep is a robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia patients.

July 25, 2025 — Data in recent staffing surveys from the American Society of Radiologic Technologists show that vacancy rates for all medical imaging disciplines are above the rates reported in 2020, according to the 2025 ASRT Radiologic Sciences Staffing and Workplace Survey. Vacancy rates represent the number of unfilled positions that are actively being recruited.

July 24, 2025 —  Royal Philips has announced a collaboration with Epic to integrate Philips’ suite of cardiac ambulatory monitoring and diagnostics services with Aura, the specialty diagnostics suite of the electronic health record (EHR) company.

This collaboration will offer the broadest cardiac care portfolio of any single service provider integrating with Aura to date. Philips will deliver a new level of interoperability between its ambulatory monitoring technologies and Epic — helping providers enhance the diagnostic process and improve patient outcomes. 

July 22, 2025 — In a collaboration between American Heart Association Ventures and the Association’s Center for Health Technology and Innovation, eight companies have been selected to participate in the American Heart Association Heart and Brain Health Accelerator.

July 21, 2025 — Long COVID patients with abnormal cardiopulmonary PET/MR findings may be more likely to develop heart and lung diseases, according to new research published in the July issue of The Journal of Nuclear Medicine. The study — which included the largest cohort of long COVID subjects with cardiopulmonary symptoms with the longest follow-up duration — suggests that abnormal cardiopulmonary PET/MR should be considered a risk factor for future cardiac and pulmonary disease and that closer monitoring is warranted in these patients.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now